Resultats globals: 10 registres trobats en 0.02 segons.
Articles, 7 registres trobats
Documents de recerca, 3 registres trobats
Articles 7 registres trobats  
1.
10 p, 1.3 MB Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy / Floros, Konstantinos V. (Philips Institute for Oral Health Research) ; Lochmann, Timothy L. (Philips Institute for Oral Health Research) ; Hu, Bin (Virginia Commonwealth University School of Medicine) ; Monterrubio, Carles (Memorial Sloan Kettering Cancer Center) ; Hughes, Mark T. (Philips Institute for Oral Health Research) ; Wells, Jason D. (Norris Cotton Cancer Center) ; Morales, Cristina Bernadó (Vall d'Hebron Institut d'Oncologia) ; Ghotra, Maninderjit S. (Philips Institute for Oral Health Research) ; Costa, Carlotta (Massachusetts General Hospital) ; Souers, Andrew J. (AbbVie Inc) ; Boikos, Sosipatros A. (Virginia Commonwealth University) ; Leverson, Joel D. (AbbVie Inc) ; Tan, Ming (University of South Alabama) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ; Koblinski, Jennifer E. (Virginia Commonwealth University School of Medicine) ; Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Paré, Laia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Miller, Todd W. (Norris Cotton Cancer Center) ; Dozmorov, Mikhail G. (Virginia Commonwealth University) ; Harada, Hisashi (Philips Institute for Oral Health Research) ; Windle, Brad E. (Philips Institute for Oral Health Research) ; Scaltriti, Maurizio (Memorial Sloan Kettering Cancer Center) ; Faber, Anthony C. (Philips Institute for Oral Health Research)
In HER2 -amplified breast cancers, HER2 inhibitors have been very successful as adjuvant therapy but not as monotherapy. Here, we demonstrate that coamplification of a HER2 intronic miRNA causes intrinsic resistance to HER2 inhibitors by indirectly down-regulating the pro-apoptotic NOXA. [...]
2018 - 10.1073/pnas.1717820115
Proceedings of the National Academy of Sciences of the United States of America, Vol. 115 (february 2018) , p. E2594-E2603  
2.
14 p, 2.2 MB Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer / Aguado, Cristina (Quirón Dexeus University Hospital) ; Teixido, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Román, Ruth (Quirón Dexeus University Hospital) ; Reyes, Roxana (Hospital Clínic i Provincial de Barcelona) ; Giménez-Capitán, Ana (Quirón Dexeus University Hospital) ; Marin, Elba (Hospital Clínic i Provincial de Barcelona) ; Cabrera, Carlos (Grup Quirónsalud (Barcelona, Catalunya)) ; Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ; Castillo, Sergi (Hospital General de Granollers) ; Muñoz, Silvia (Hospital General de Granollers) ; Arcocha, Ainara (Hospital Clínic i Provincial de Barcelona) ; López-Vilaró, Laura (Institut d'Investigació Biomèdica Sant Pau) ; Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ; Aldeguer, Erika (Quirón Dexeus University Hospital) ; Rodríguez, Sonia (Quirón Dexeus University Hospital) ; Moya, Irene (Grup Quirónsalud (Barcelona, Catalunya)) ; Viteri, Santiago (Quiron Salud Group) ; Cardona, Andrés Felipe (Clínica del Country) ; Palmero, Ramon (L'Hospitalet) ; Sainz, Cristina (Centro de Investigación Biomédica en Red de Cáncer) ; Mesa-Guzmán, Miguel (Universidad Pública de Navarra) ; Lozano, Maria D. (Universidad Pública de Navarra) ; Aguilar-Hernández, Andrés (Grup Quirónsalud (Barcelona, Catalunya)) ; Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ; González-Cao, María (Grup Quirónsalud (Barcelona, Catalunya)) ; Gonzalvo, Elena (Hospital Clínic i Provincial de Barcelona) ; Leenders, William P. J. (Radboud Institute for Molecular Life Sciences) ; Rosell, Rafael (Universitat Autònoma de Barcelona. Departament de Medicina) ; Montuenga, Luis M. (Universidad Pública de Navarra) ; Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ; Molina-Vila, Miguel Angel (Quirón Dexeus University Hospital) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona)
We studied MET alterations in 474 advanced non-small-cell lung cancer (NSCLC) patients by nCounter, an RNA-based technique. We identified 3% with MET Δex14 mRNA and 3. 5% with very-high MET mRNA expression, a surrogate of MET amplification. [...]
2020 - 10.1002/1878-0261.12861
Molecular Oncology, Vol. 15 (december 2020) , p. 350-363  
3.
13 p, 2.0 MB Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer / Garrido-Castro, Ana C. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Saura, Cristina (SOLTI Breast Cancer Research Group, Barcelona) ; Barroso-Sousa, Romualdo (Present Address: Hospital Sírio-Libanês, Brasilia, Brazil) ; Guo, Hao (Dana-Farber Cancer Institute. Division of Biostatistics, Department of Data Sciences) ; Ciruelos, Eva (Hospital Universitario 12 de Octubre (Madrid)) ; Bermejo, Begoña (CIBERONC-ISCIII. Clinic University Hospital, INCLIVA Biomedical Research Institute) ; Gavilá, Joaquin (Fundación Instituto Valenciano De Oncología) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ; Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Paré, Laia (SOLTI Breast Cancer Research Group) ; Céliz, Pamela (SOLTI Breast Cancer Research Group) ; Villagrasa, Patricia (SOLTI Breast Cancer Research Group) ; Li, Yisheng (The University of Texas MD Anderson Cancer Center. Department of Biostatistics, Division of Basic Sciences) ; Savoie, Jennifer (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Xu, Zhan (Northern Arizona University. School of Communication) ; Arteaga, Carlos L. (UT Southwestern Medical Center. Harold C. Simmons Comprehensive Cancer Center) ; Krop, Ian E. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Solit, David B. (Memorial Sloan Kettering Cancer Center) ; Mills, Gordon B. (The University of Texas MD Anderson Cancer Center. Present Address: Division of Basic Science Research, Department of Systems Biology) ; Cantley, Lewis C. (Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College) ; Winer, Eric P. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Lin, Nancy U. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Rodon, Jordi (The University of Texas MD Anderson Cancer Center. Present Address: Department of Investigational Cancer Therapeutics) ; Universitat Autònoma de Barcelona
Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. [...]
2020 - 10.1186/s13058-020-01354-y
Breast cancer research, Vol. 22 (november 2020)  
4.
13 p, 6.8 MB Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity / Prat, Aleix (Vall d'Hebron Institut d'Oncologia) ; Adamo, Barbara (Vall d'Hebron Institut d'Oncologia) ; Fan, Cheng (Lineberger Comprehensive Cancer Center, University of North Carolina) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Vidal, Maria (Vall d'Hebron Institut d'Oncologia) ; Galván, Patricia (Vall d'Hebron Institut d'Oncologia) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Palmer, Héctor G. (Vall d'Hebron Institut d'Oncologia) ; Dawood, Shaheenah (Department of Medical Oncology, Dubai Hospital) ; Rodón, Jordi (Vall d'Hebron Institut d'Oncologia) ; Cajal, Santiago Ramon y (Hospital Universitari Vall d'Hebron) ; Campo, Josep Maria Del (Vall d'Hebron Institut d'Oncologia) ; Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
To improve our understanding of the biological relationships among different types of cancer, we have characterized variation in gene expression patterns in a set of 1,707 samples representing 6 human cancer types (breast, ovarian, brain, colorectal, lung adenocarcinoma and squamous cell lung cancer). [...]
2013 - 10.1038/srep03544
Scientific reports (Nature Publishing Group), Vol. 3 (december 2013)  
5.
10 p, 1.9 MB Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer / Codony Servat, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cuatrecasas, Miriam ; Asensio, Elena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Montironi, Carla (Hospital Clínic i Provincial de Barcelona) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Marín Aguilera, Mercedes (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Horndler, Carlos (Hospital Miguel Servet) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ; Jares, Pedro (Hospital Clínic i Provincial de Barcelona) ; Reig, Oscar (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Victoria, Iván (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Gaba, Lydia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ; Alonso, Vicente (Hospital Miguel Servet) ; Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Fernández-Martos, Carlos (Fundació Institut Valencià d'Oncologia) ; Feliu, Jaime (Centro de Investigación Biomédica en Red de Cáncer) ; Méndez, Jose Carlos (Centro Oncológico de Galicia) ; Méndez, Miguel (Hospital de Móstoles) ; Gallego, Javier (Hospital de Elche) ; Salud, Antonieta (Hospital Arnau de Vilanova) ; Rojo, Federico (Pathology Department, Fundación Jiménez Diaz University) ; Castells, Antoni (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health) ; Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Universitat Autònoma de Barcelona
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786  
6.
10 p, 3.3 MB Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts / Morancho, Beatriz (Hospital Universitari Vall d'Hebron) ; Zacarías-Fluck, Mariano ; Esgueva, Antonio (Hospital Universitari Vall d'Hebron) ; Bernadó Morales, Cristina (Hospital Universitari Vall d'Hebron) ; Cosimo, Serena Di (Division of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy) ; Prat, Aleix (Hospital Universitari Vall d'Hebron) ; Cortés, Javier (Hospital Universitari Vall d'Hebron) ; Arribas, Joaquín (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Rubio, Isabel T. (Hospital Universitari Vall d'Hebron)
The pleiotropic cytokine IL-6 accelerates the progression of breast cancer in a variety of preclinical models through the activation of the STAT3 (signal transducer and activator of transcription 3) signaling pathway. [...]
2016 - 10.18632/ONCOTARGET.11815
Oncotarget, Vol. 7 (september 2016) , p. 67956-67965  
7.
12 p, 915.6 KB PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers / Bastien, Roy R. L. (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ; Rodríguez-Lescure, Álvaro (Hospital Universitario de Elche (Elx, País Valencià)) ; Ebbert, Mark T.W. (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ; Prat, Aleix (Universitat Autònoma de Barcelona. Departament de Medicina) ; Munárriz, Blanca (Hospital Universitari i Politècnic La Fe (València)) ; Rowe, Leslie (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ; Miller, Patricia (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ; Ruiz Borrego, Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Anderson, Daniel (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ; Lyons, Bradley (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ; Álvarez, Isabel (Hospital de Donostia (Sant Sebastià, País Basc)) ; Dowell, Tracy (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ; Wall, David (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ; Seguí, Miguel Ángel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Barley, Lee (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ; Boucher, Kenneth M. (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ; Alba, Emilio (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Pappas, Lisa (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ; Davis, Carole A. (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ; Aranda, Ignacio (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Fauron, Christiane (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ; Stijleman, Inge J. (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ; Palacios, José (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Antón, Antonio (Hospital Universitario Miguel Servet (Saragossa, Aragó)) ; Carrasco, Eva (GEICAM. Spanish Breast Cancer Research Group (Madrid)) ; Caballero, Rosalía (GEICAM. Spanish Breast Cancer Research Group (Madrid)) ; Ellis, Matthew J. (Washington University. Department of Oncology (St. Louis, Estats Units d'Amèrica)) ; Nielsen, Torsten O. (University of British Columbia. Department of Anatomical Pathology (Vancouver, Canadà)) ; Perou, Charles M. (University of North Carolina at Chapel Hill. Lineberger Comprehensive Cancer Center (Chapel Hill, Estats Units d'Amèrica)) ; Astill, Mark (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ; Bernard, Philip S. (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ; Martín, Miguel (Hospital General Universitario Gregorio Marañón)
Background: Many methodologies have been used in research to identify the "intrinsic" subtypes of breast cancer commonly known as Luminal A, Luminal B, HER2-Enriched (HER2-E) and Basal-like. The PAM50 gene set is often used for gene expression-based subtyping; however, surrogate subtyping using panels of immunohistochemical (IHC) markers are still widely used clinically. [...]
2012 - 10.1186/1755-8794-5-44
BMC medical genomics, Vol. 15, N. 44 (October 2012) , p. 1-9
4 documents

Documents de recerca 3 registres trobats  
1.
175 p, 2.8 MB Caracterización de la expresión de ácido ribonucleico mensajero en distintos subtipos histológicos de carcinoma basocelular / Bassas Freixas, Patricia ; García-Patos Briones, Vicente, dir. (Universitat Autònoma de Barcelona. Departament de Medicina) ; Prat Aparicio, Aleix, dir. ; Universitat Autònoma de Barcelona. Departament de Medicina
El carcinoma basocelular (CBC) es el tumor maligno más frecuente en el ser humano y su incidencia está en aumento. Existe un subgrupo de CBC que presentan un comportamiento más agresivo, son más destructivos e invasivos y tienen un mayor riesgo de recurrencia y de metástasis. [...]
Basal cell carcinomas (BCC) are the most common cancers worldwide and their incidence is increasing annualy. A subset of BCC behaves more aggressively and are associated with a higher risk of recurrence, local tissue destruction, deeper invasion, subclinical spread, morbidity and distant metastasis risk. [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2019.  
2.
137 p, 1.5 MB Implicación prónostica de la infección por virus del papiloma humano en tumores de orofaringe y cavidad oral localmente avanzados e irresecables / Rodríguez Freixinós, Víctor ; Giralt López de Sagredo, Jorge Luis, dir. ; Prat Aparicio, Aleix, dir. ; Universitat Autònoma de Barcelona. Departament de Medicina
En la última década, la incidencia de los tumores escamosos de cabeza y cuello relacionados con el virus del Papiloma Humano (HPV), principalmente en los tumores de orofaringe, ha aumentado considerablemente, siendo considerados una entidad clínica asociada a características etiológicas, clínicas y pronósticas diferenciadas del subgrupo de tumores HPV negativos. [...]
Over the past decade, there has been a significant increase in the incidence of HPV positive head and neck cancers (HNC), particularly in tumors arising in the oropharynx, comprising approximately 60% of all cases. [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2017.  
3.
27 p, 945.8 KB Phenotypic and molecular characterization of the intrinsic molecular subtypes of breast cancer / Prat Aparicio, Aleix ; Albanell, Joan, dir. (Hospital del Mar (Barcelona, Catalunya)) ; Universitat Autònoma de Barcelona. Departament de Medicina
La implementación de programas de cribaje y/o de prevención junto a terapias innovadoras está disminuyendo la mortalidad por cáncer de mama. Ahora bien, más de 120. 000 muertes anuales ocurren en Estados Unidos y en Europa por esta causa. [...]
Implementation of screening/prevention programs and novel treatment strategies is decreasing breast cancer mortality. However, more than 120,000 estimated deaths due to breast cancer are expected annually in the US and Europe combined. [...]

Bellaterra : Universitat Autònoma de Barcelona, 2014  

Vegeu també: autors amb noms similars
2 Prat, A
4 Prat, A.
1 Prat, Alba
1 Prat, Albert
1 Prat, Alexandre
1 Prat, Andrea
1 Prat, Andreu
4 Prat, Angels
1 Prat, Anna
4 Prat, Àngels
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.